Matica Bio inks AAV vector contract manufacturing deal with US firm Cirsium Biosciences

Matica Biotechnology, a U.S. affiliate of Korea’s CHA Biotech, said Tuesday that it has signed a contract development and manufacturing deal with Cirsium Biosciences, a U.S. biotech firm developing plant-based adeno-associated virus (AAV) technology. Under the deal, Matica Bio will develop processes and analytical methods needed for the AAV vector and manufacture the vectors for Cirsium Biosciences. Other details of the deal, such as upfront payment, were kept confidential by mutual agreement between the two companies, Matica Bio said. The AAV vector is an engineered virus designed to deliver genetic materials into target cells harmlessly. It is gaining market attention in the field of gene therapy, as it allows targeted and long-term delivery with a lower immune response compared to other viral vectors. With the cost and efficiency of AAV manufacturing remaining significant limitations, Matica Bio said the two sides expect their partnership to enable faster and broader access for patients. “Partnering with Cirsium means working alongside a company committed to advancing innovation iWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times